NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Dianthus Therapeutics, Inc. DNTH
10 fiscal years on record · USD · FY2025 reported · SEC filings only
$-162.3M
Growth
USD 2.0M
Revenue, FY2025 · full 10-year series below
Revenue $M
Net income $M
FY2025 · Revenue 2.0 · Net income -162.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−7973 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -8739.3% · Net -7973.3%
ROE
FY2025 · ROE -38.4%
Each USD of equity lost 38 cents this year.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | · | · | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | · | · | · | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −4.20 | −2.55 | −8.45 | −32.57 | −1.29 | −1.71 | −2.07 | −3.13 | −19.12 | −65.15 |
| Dividend / sh $ | 0.00 | 0.00 | 0.00 | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | −38.4 | −32.6 | −70.0 | · | −112.3 | −52.6 | −53.5 | −111.1 | · | · |
| Shares out B | 0.04 | 0.03 | 0.01 | 0.00 | 0.06 | 0.05 | 0.04 | 0.03 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 38 reconciliationsAUDITED
Reconciled in 10 of 19 fiscal years. 38 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016